Lipid nanoparticle compositions for antisense oligonucleotides delivery
Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.
1. A lipid nanoparticle composition comprising:
a cationic liposome;
a targeting agent; and
a net positively-charged core comprising an albumin-polycation conjugate,
wherein the cationic liposome encapsulates the net positively-charged core to form a lipid-coated albumin nanoparticle (LCAN).
2. The lipid nanoparticle composition of claim 1 , the net positively-charged core further comprising a therapeutic agent selected from the group consisting of nucleic acids, proteins, polysaccharides, lipids, radioactive substances, prodrugs, and combinations thereof.
3. The lipid nanoparticle composition of claim 2 , wherein the therapeutic agent comprises an antisense oligonucleotide (ASO) selected from the group consisting of
an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; and
an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1.
4. The lipid nanoparticle composition of claim 1 , wherein the albumin is human serum albumin (HSA).
5. The lipid nanoparticle composition of claim 1 , wherein the albumin-polycation conjugate comprises pentaethylenehexamine (PEHA) or tetraethylenepentamine.
6. The lipid nanoparticle composition of claim 3 , wherein the antisense oligonucleotide is a compound having a sequence comprising 5′ gctgcatgatctccttggcg 3′ (Seq. Id. No.: 1), targeted to a nucleic acid molecule encoding human Akt-1, and which modulates the expression of Akt-1.
7. The lipid nanoparticle composition of claim 3 , wherein the antisense oligonucleotide is a compound having a sequence comprising 5′aatgagccaccagtgtccaa 3′ (Seq. Id. No.: 2), targeted to a nucleic acid molecule encoding human HIF-1, and which modulates the expression of HIF-1.
8. The lipid nanoparticle composition of claim 1 , wherein the targeting agent comprises a moiety selected from RGD peptides, galactose-containing moieties, transferrin, folate, low density lipoprotein, epidermal growth factors, and antibodies.
9. The lipid nanoparticle composition of claim 1 , wherein the targeting agent comprises cRGDfC or folate.
10. The lipid nanoparticle composition of claim 1 , wherein the targeting agent comprises a conjugate selected from the group consisting of folate-PEG-CHEMS (folate-polyethylene glycol-cholesteryl hemisuccinate), folate-PEG-DSPE (folate-polyethylene glycol-distearoyl phosphatidylethanolamine), and cRGDfC-PEG-DSPE (cyclo(RGDfC)-polyethylene glycol-distearoyl phosphatidylethanolamine).
11. A pharmaceutical composition comprising:
a lipid nanoparticle composition comprising
a cationic liposome;
a targeting agent; and
a net positively-charged core comprising an albumin-polycation conjugate and a therapeutic agent, wherein the cationic liposome encapsulates the net positively-charged core to form a lipid-coated albumin nanoparticle (LCAN); and
a pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11 , wherein the therapeutic agent is an antisense oligonucleotide (ASO) selected from the group consisting of an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; and an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1.
13. A method of making a lipid-coated albumin nanoparticle (LCAN), the method comprising
synthesizing a HSA-PEHA conjugate;
preparing a mixture of lipids comprising a cationic lipid and a targeting agent;
adding the mixture of lipids to the HSA-PEHA conjugate, wherein the mixture of lipids form a cationic liposome that encapsulates the HSA-PEHA conjugate; and
adding a therapeutic agent to the mixture of lipids and the HSA-PEHA conjugate to obtain an LCAN precursor.
14. The method of claim 13 , wherein the therapeutic agent comprises an antisense oligonucleotide (ASO) selected from the group consisting of an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; and an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1.
15. The method of claim 13 , further comprising adding the targeting agent to the cationic liposome and the HSA-PEHA conjugate.
16. The method of claim 15 , wherein the lipids comprising a targeting agent selected from the group consisting of folate-PEG-CHEMS (folate-polyethylene glycol-cholesteryl hemisuccinate), folate-PEG-DSPE (folate-polyethylene glycol-distearoyl phosphatidylethanolamine), and cRGDfC-PEG-DSPE (cyclo(RGDfC)-polyethylene glycol-distearoyl phosphatidylethanolamine).
17. A method of treating a cancer or infectious disease, the method comprising administering an effective amount of a pharmaceutical composition of claim 11 to a patient in need thereof.
18. The method of claim 17 , wherein the cancer is selected from the group consisting of brain cancer, bladder cancer, lung cancer, breast cancer, melanoma, skin cancer, epidermal carcinoma, colon and rectal cancer, non-Hodgkin lymphoma, endometrial cancer, pancreatic cancer, kidney cancer, prostate cancer, leukemia thyroid cancer, head and neck cancer, ovarian cancer, hepatocellular cancer, cervical cancer, sarcomas, gastric cancers, multiple myeloma, lymphomas, gastrointestinal cancer, and uterine cancer.
19. The lipid nanoparticle composition of claim 5 , wherein the albumin-polycation conjugate is a HSA-PEHA conjugate.
20. The lipid nanoparticle composition of claim 1 , wherein the albumin-polycation conjugate comprises polyethylenimine (PEI).
21. The lipid nanoparticle composition of claim 1 , wherein the targeting agent is coated on the surface of the cationic liposome.
22. The lipid nanoparticle composition of claim 1 , wherein the polycation comprises PEHA, wherein the mole ratio of the PEHA to the albumin is between 10 to 1 and 12 to 1.
23. The lipid nanoparticle composition of claim 22 , wherein the mole ratio of the PEHA to the albumin is about 11 to 1.
24. The lipid nanoparticle composition of claim 1 , wherein the cationic liposome comprises a cationic lipid selected from the group consisting of: 3β-[N(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride (DC-Chol); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); dimethyldioctadecylammonium bromide salt (DDAB); 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine chloride (DL-EPC); N-[1-(2,3-dioleyloyx) propyl]-N—N—N-trimethyl ammonium chloride (DOTMA); N-[1-(2,3-dioleyloyx) propyl]-N—N—N-dimethyl ammonium chloride (DODMA); 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine chloride (DOEPC); N,N-dioctadecyl-N,N-dimethylammonium chloride (DODAC); N-(1-(2,3-dioleyloxy)propyl)-N-2-(sperminecarboxamido)ethyl)-N,N-dimethylammonium trifluoracetate (DOSPA); 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide (DMRIE); dioctadecylamidoglycylspermine (DOGS); neutral lipids conjugated to cationic modifying groups; and combinations thereof.
25. The lipid nanoparticle composition of claim 1 , further comprising a stabilizing component.
26. The lipid nanoparticle composition of claim 25 , wherein the stabilizing component is selected from D-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS) or mPEG-DSPE.
27. The method of claim 13 , wherein the mixture of lipids comprises DOTAP, soyPC, and TPGS, and wherein the targeting agent comprises cRGDfC-PEG-DSPE.
28. The method of claim 27 , wherein the molar ratio of DOTAP:soyPC:TPGS:cRGD-PEG-DSPE is about 25:70:4:1.
29. The lipid nanoparticle composition of claim 1 , wherein the lipid nanoparticle has a particle size under about 300 nm.
30. The lipid nanoparticle composition of claim 1 , wherein the lipid nanoparticle has a particle size under about 150 nm.
31. The lipid nanoparticle composition of claim 1 , wherein the albumin-polycation conjugate comprises spermine or spermidine.
32. The lipid nanoparticle composition of claim 1 , wherein the polycation is selected from the group consists of polyethylenimine (PEI); pentaethylenehexamine (PEHA); tetraethylenepentamine; spermine; spermidine; poly(L-lysine); poly(amido amine) (PAMAM) dendrimers; polypropyleneimine dendrimers; poly(2-dimethylamino ethyl)-methacrylate (pDMAEMA); chitosan; tris(2-aminoethyl)amine and its methylated derivatives; and combinations thereof.